Abstract
Polycystic ovarian syndrome (PCOS), a metabolic disorder, manifests itself in a variety of ways. In this cross-sectional study, we evaluated the IL-6-174 G/C promoter gene polymorphism in adult PCOS women and its relationship to circulating levels and metabolic risk indicators. A total of 298 women between the ages between 15 and 35 years were chosen, 126 of whom had PCOS, and 172 of whom did not (control group). Both groups were further divided into subgroups of obese and lean women. The lipid profile, serum IL-6 level, and Homeostatic Model Assessment (HOMA) index were all examined. By using PCR-RFLP, the genotype of IL-6-174 G/C was identified. Women in the PCOS and non-PCOS groups showed significant variations in genotype frequencies and metabolic risk indicators. In PCOS compared to non-PCOS, there was a stronger correlation between the mutant ‘C’ allele of IL-6-174 G/C (p<0.0001; OR=1.91; 95% CI=1.38-2.66). Women with PCOS (61.2%) were significantly more associated with both the homozygous CC and heterozygous GC genotypes of IL-6-174 G/C in respect of WHR>0.85 than non-PCOS women (59.2%). In PCOS women, the distribution of the mutant genotypes CC and GC of the IL-6-174 G/C gene was likewise significantly different from GG, with higher WHR (p=0.0191), HOMA index (p=0.031), and serum IL-6 level (p=0.0094). These findings imply that the IL-6-174 G/C promoter mutant CC genotype was substantially related with increased circulating IL-6 levels, and that the presence of IR may be a risk indicator for the development of the metabolic syndrome (MetS) in PCOS women.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by Indian Council of Medical Research (ICMR), New Delhi, India (No. 5/10/2/2006-RHN).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional ethics committee, King George's Medical University, Lucknow
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Polycystic ovarian syndrome (PCOS), a metabolic disorder, manifests itself in a variety of ways. In this cross-sectional study, we evaluated the IL-6-174 G/C promoter gene polymorphism in adult PCOS women and its relationship to circulating levels and metabolic risk indicators. A total of 298 women between the ages between 15 and 35 years were chosen, 126 of whom had PCOS, and 172 of whom did not (control group). Both groups were further divided into subgroups of obese and lean women. The lipid profile, serum IL-6 level, and Homeostatic Model Assessment (HOMA) index were all examined. By using PCR-RFLP, the genotype of IL-6-174 G/C was identified. Women in the PCOS and non-PCOS groups showed significant variations in genotype frequencies and metabolic risk indicators. In PCOS compared to non-PCOS, there was a stronger correlation between the mutant C allele of IL-6-174 G/C (p<0.0001; OR=1.91; 95% CI=1.38-2.66). Women with PCOS (61.2%) were significantly more associated with both the homozygous CC and heterozygous GC genotypes of IL-6-174 G/C in respect of WHR>0.85 than non-PCOS women (59.2%). In PCOS women, the distribution of the mutant genotypes CC and GC of the IL-6-174 G/C gene was likewise significantly different from GG, with higher WHR (p=0.0191), HOMA index (p=0.031), and serum IL-6 level (p=0.0094). These findings imply that the IL-6-174 G/C promoter mutant CC genotype was substantially related with increased circulating IL-6 levels, and that the presence of IR may be a risk indicator for the development of the metabolic syndrome (MetS) in PCOS women.
Data Availability
All data produced in the present work are contained in the manuscript.
